FORMULATION AND EVALUATION OF BUCCAL MUCOADHESIVE TABLETS OF RIZATRIPTAN
Brij Kishor* Jogendra Singh, Muraree Lal, Sapna Avinash Kondalkar, Deepak Tripathi, Avinash K Kondalkar
ABSTRACT
Migraine, defined as headache occurring on 15 days per month for more than 3 months with migraine symptoms on 8 days per month is a debilitating ailment affecting 0.5% to 5% of the general population. So, The ideal properties of medications related to migraine is the dosage form must be fast dissolving and avoid first pass metabolism Mucoadhesive buccal films provide several distinct advantages, including their small thickness, ease of administration, direct systemic absorption followed by a prolonged effect, and both local and systemic effects. The goal of this study was to create and test a Rizatriptan mucoadhesive for an anti-migraine effect. The mucoadhesive tablets were evaluated for a series of parameters such as hardness, thickness, weight variation, friability, drug content, in vitro swelling study, in mucoadhesive strength, and in-vitro drug release study. Results showed that maximum drug content of 99.85±0.23 is present in F5 formulation. The thickness & hardness for F5 was seen to be 3.14±0.07mm & 4.3±0.2 kg/cm2. The weigh variation &friability for F5 was noted to be 249±4mg & 0.825±0.047% respectively. At 12 hrs maximum swelling index of 106.65 is observed in F5 again. The In vitro drug release study of buccal tablet suggest that % Cumulative Drug Release for F5 was seen 99.78% which is highest among all formulations. When the regression coefficient values of were compared, it was observed that ‘r2’ values of Korsmeyer-Peppas was maximum i.e. 0.967. In conclusion these Rizatriptan mucoadhesive tablets appear promise as a controlled drug delivery strategy, which can lead to improved bioavailability and therapeutic efficacy.
[Full Text Article]